
Shalby (SHALBY) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
2.6B
Gross Profit
993.2M
37.50%
Operating Income
46.1M
1.74%
Net Income
-121.9M
-4.60%
Balance Sheet Metrics
Total Assets
17.0B
Total Liabilities
7.1B
Shareholders Equity
10.0B
Debt to Equity
0.71
Cash Flow Metrics
Operating Cash Flow
433.2M
Free Cash Flow
-66.6M
Revenue & Profitability Trend
Shalby Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 10.9B | 9.3B | 8.0B | 7.0B | 4.3B |
Cost of Goods Sold | 6.3B | 5.1B | 4.4B | 3.9B | 2.5B |
Gross Profit | 4.5B | 4.2B | 3.6B | 3.0B | 1.8B |
Gross Margin % | 41.6% | 45.6% | 45.6% | 43.6% | 42.1% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 294.7M | 251.8M | 147.1M | 52.6M |
Other Operating Expenses | 1.3B | 578.1M | 540.0M | 477.2M | 257.7M |
Total Operating Expenses | 1.3B | 872.8M | 791.8M | 624.3M | 310.3M |
Operating Income | 668.5M | 1.3B | 937.7M | 826.2M | 557.3M |
Operating Margin % | 6.1% | 13.8% | 11.7% | 11.8% | 12.9% |
Non-Operating Items | |||||
Interest Income | - | 50.1M | 79.3M | 72.2M | 52.3M |
Interest Expense | 387.1M | 144.0M | 79.7M | 58.8M | 29.1M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 557.3M | 1.3B | 1.0B | 791.5M | 550.6M |
Income Tax | 538.1M | 446.9M | 343.7M | 251.8M | 126.9M |
Effective Tax Rate % | 96.6% | 34.9% | 33.7% | 31.8% | 23.1% |
Net Income | 19.2M | 835.0M | 676.8M | 539.7M | 423.6M |
Net Margin % | 0.2% | 9.0% | 8.5% | 7.7% | 9.8% |
Key Metrics | |||||
EBITDA | 1.6B | 1.9B | 1.6B | 1.3B | 968.8M |
EPS (Basic) | - | ₹7.83 | ₹6.30 | ₹5.00 | ₹3.97 |
EPS (Diluted) | - | ₹7.83 | ₹6.30 | ₹5.00 | ₹3.97 |
Basic Shares Outstanding | - | 107336146 | 107422921 | 108009770 | 108009770 |
Diluted Shares Outstanding | - | 107336146 | 107422921 | 108009770 | 108009770 |
Income Statement Trend
Shalby Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 347.8M | 271.8M | 122.4M | 555.5M | 64.7M |
Short-term Investments | 1.1B | 806.5M | 1.5B | 796.8M | 926.1M |
Accounts Receivable | 1.8B | 1.4B | 1.1B | 1.0B | 946.9M |
Inventory | 3.2B | 2.4B | 1.9B | 1.2B | 230.5M |
Other Current Assets | 231.5M | 38.8M | 21.7M | 6.5M | 4.9M |
Total Current Assets | 6.6B | 5.5B | 5.2B | 4.5B | 2.7B |
Non-Current Assets | |||||
Property, Plant & Equipment | 8.9B | 4.0B | 3.1B | 2.9B | 2.5B |
Goodwill | 1.4B | 1.3B | 316.8M | 311.8M | 273.1M |
Intangible Assets | 241.4M | 182.0M | 113.7M | 108.8M | 70.0M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 392.0M | 381.2M | 280.0K | 50.9M | 25.7M |
Total Non-Current Assets | 10.5B | 10.6B | 7.6B | 7.4B | 7.3B |
Total Assets | 17.0B | 16.1B | 12.8B | 11.9B | 10.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.2B | 1.3B | 879.2M | 707.4M | 575.7M |
Short-term Debt | 3.0B | 1.5B | 789.4M | 733.3M | 93.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 139.4M | 74.8M | 50.8M | 41.9M | 32.8M |
Total Current Liabilities | 4.6B | 3.2B | 1.9B | 1.7B | 817.5M |
Non-Current Liabilities | |||||
Long-term Debt | 1.8B | 2.3B | 1.0B | 1.0B | 447.6M |
Deferred Tax Liabilities | 631.4M | 350.2M | 434.4M | 305.6M | 227.8M |
Other Non-Current Liabilities | 82.5M | 10.0K | 113.9M | -10.0K | 10.0K |
Total Non-Current Liabilities | 2.5B | 2.8B | 1.6B | 1.4B | 802.1M |
Total Liabilities | 7.1B | 6.0B | 3.5B | 3.2B | 1.6B |
Equity | |||||
Common Stock | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
Retained Earnings | - | 4.5B | 3.8B | 3.2B | 2.8B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 10.0B | 10.1B | 9.3B | 8.8B | 8.3B |
Key Metrics | |||||
Total Debt | 4.8B | 3.8B | 1.8B | 1.7B | 541.3M |
Working Capital | 2.0B | 2.3B | 3.2B | 2.8B | 1.9B |
Balance Sheet Composition
Shalby Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 557.3M | 1.3B | 1.0B | 791.5M | 550.6M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 10.5M | 10.1M | 8.2M | 0 | - |
Working Capital Changes | -1.2B | -1.1B | -635.8M | -1.1B | -15.2M |
Operating Cash Flow | -417.0M | 252.3M | 412.8M | -282.8M | 519.1M |
Investing Activities | |||||
Capital Expenditures | -700.8M | -451.8M | -177.4M | -482.8M | -208.6M |
Acquisitions | - | - | - | 0 | -10.5M |
Investment Purchases | -5.2B | -2.8B | -5.3B | -4.3B | -623.4M |
Investment Sales | 5.5B | 3.6B | 4.8B | 4.1B | 280.5M |
Investing Cash Flow | -433.5M | 329.6M | -695.4M | -675.5M | -561.9M |
Financing Activities | |||||
Share Repurchases | - | 0 | -75.4M | 0 | - |
Dividends Paid | -129.6M | -129.6M | -108.0M | -108.0M | -54.0M |
Debt Issuance | 1.5B | 1.5B | 269.2M | 1.1B | 0 |
Debt Repayment | -393.0M | -581.2M | -402.6M | -86.1M | -201.8M |
Financing Cash Flow | 999.4M | -1.3B | -166.3M | 1.0B | -255.8M |
Free Cash Flow | -757.9M | -275.1M | 492.9M | -564.8M | 582.9M |
Net Change in Cash | 148.8M | -707.6M | -448.9M | 43.5M | -298.6M |
Cash Flow Trend
Shalby Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
1,126.78
Forward P/E
21.58
Price to Book
1.99
Price to Sales
2.00
PEG Ratio
21.58
Profitability Ratios
Profit Margin
0.57%
Operating Margin
1.74%
Return on Equity
0.19%
Return on Assets
2.52%
Financial Health
Current Ratio
1.44
Debt to Equity
9.69
Beta
0.46
Per Share Data
EPS (TTM)
₹0.18
Book Value per Share
₹101.79
Revenue per Share
₹111.51
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
shalby | 21.8B | 1,126.78 | 1.99 | 0.19% | 0.57% | 9.69 |
Max Healthcare | 1.2T | 115.26 | 13.09 | 12.10% | 15.31% | 32.09 |
Apollo Hospitals | 1.0T | 72.09 | 12.70 | 18.85% | 6.63% | 90.89 |
Indraprastha Medical | 42.7B | 26.50 | 7.15 | 26.98% | 12.21% | 5.49 |
Dr. Agarwal's Eye | 20.7B | 37.83 | 9.87 | 29.80% | 13.76% | 158.94 |
GPT Healthcare | 13.0B | 26.09 | 5.25 | 21.41% | 12.26% | 14.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.